ESPOO – October 29, 2026 -- Valmet Oyj's third-quarter orders received rose 30 percent to EUR 1,408 million (EUR 1,083 million), or 25 percent organically, while comparable EBITA climbed 6 percent to EUR 169 million (EUR 159 million).
Biomaterial capital orders reach EUR 552 million on China and Asia-Pacific wins
Growth came from strong biomaterial services intake, continued expansion in Process Performance Solutions and a strong quarter in biomaterial capital projects. Biomaterial capital orders totaled EUR 552 million, including major project wins in China and Asia-Pacific. Biomaterial services orders grew 12 percent organically, with growth across regions, service categories and business areas.
Process Performance Solutions posted 3 percent organic order growth in a low-growth market and a comparable EBITA margin of 20.2 percent.
Severn consolidation and cost cuts lift Q3 comparable EBITA to EUR 169 million
Net sales increased 5 percent to EUR 1,360 million (EUR 1,295 million). The EBITA gain reflects the consolidation of Severn Group, now Engineered Severe Service, from July 1, 2026, and efficiency and cost reduction actions under the Lead the Way strategy. The comparable EBITA margin held near last year's level at 12.4 percent (12.3%).
Earnings per share fell to EUR 0.38 (EUR 0.46) and adjusted EPS to EUR 0.48 (EUR 0.54), on lower operating profit and higher financing expenses.
Nine-month cash flow from operations drops to EUR 310 million
January-September orders were flat at EUR 3,874 million (EUR 3,936 million). Net sales grew 5 percent to EUR 3,920 million (EUR 3,720 million). Comparable EBITA reached EUR 434 million (EUR 423 million), with the margin at 11.1 percent (11.4%). EPS was EUR 0.97 (EUR 0.95) and adjusted EPS EUR 1.21 (EUR 1.18). Operating cash flow declined to EUR 310 million from EUR 391 million.
Valmet books about EUR 10 million in Q4 costs to prepare a possible two-company split
The Board launched a strategic review on July 24, 2026, to assess separating Biomaterial Solutions and Services from Process Performance Solutions into two standalone companies listed on Nasdaq Helsinki. No decision has been made. Valmet will start activities in Q4 to strengthen the segments' readiness to operate independently, at costs of roughly EUR 10 million.
Review costs will be reported as items affecting comparability and will not hit comparable EBITA. An update is due no later than the full-year 2026 results.
Valmet holds 2026 guidance and targets 15 percent EBITA margin by 2030
The company reiterated that 2026 net sales will stay at the 2025 level of EUR 5,197 million, and that comparable EBITA will match or exceed EUR 620 million.
For October 2026 to March 2027, Valmet expects low year-over-year growth in the Process Performance Solutions market and a broadly unchanged Biomaterial Solutions and Services market. It expects the biomaterial services market to stabilize in coming quarters. Geopolitical and economic uncertainty remains high.
CEO Thomas Hinnerskov called the EBITA result "progress, but not the destination." Valmet's 2030 targets are 5 percent organic growth, a 15 percent comparable EBITA margin and a 20 percent return on capital employed.